JP2021514479A - 全身性慢性炎症加齢を測定する方法 - Google Patents
全身性慢性炎症加齢を測定する方法 Download PDFInfo
- Publication number
- JP2021514479A JP2021514479A JP2020567440A JP2020567440A JP2021514479A JP 2021514479 A JP2021514479 A JP 2021514479A JP 2020567440 A JP2020567440 A JP 2020567440A JP 2020567440 A JP2020567440 A JP 2020567440A JP 2021514479 A JP2021514479 A JP 2021514479A
- Authority
- JP
- Japan
- Prior art keywords
- immune
- sci
- cxcl9
- aging
- age
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000032683 aging Effects 0.000 title claims abstract description 68
- 230000009885 systemic effect Effects 0.000 title claims description 17
- 208000037976 chronic inflammation Diseases 0.000 title description 13
- 230000006020 chronic inflammation Effects 0.000 title description 13
- 238000000034 method Methods 0.000 claims abstract description 114
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 81
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 73
- 102100023688 Eotaxin Human genes 0.000 claims abstract description 34
- 102100034221 Growth-regulated alpha protein Human genes 0.000 claims abstract description 34
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 34
- 101710139422 Eotaxin Proteins 0.000 claims abstract description 33
- 101100449532 Homo sapiens CXCL1 gene Proteins 0.000 claims abstract description 31
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 28
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 claims abstract description 26
- 210000002966 serum Anatomy 0.000 claims abstract description 20
- 230000001684 chronic effect Effects 0.000 claims abstract description 18
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims abstract description 9
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims abstract description 6
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims abstract 5
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims abstract 5
- 108700012411 TNFSF10 Proteins 0.000 claims abstract 5
- 239000011324 bead Substances 0.000 claims description 23
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 19
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 230000002596 correlated effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 9
- 238000004422 calculation algorithm Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 3
- 238000007837 multiplex assay Methods 0.000 claims description 2
- 238000010586 diagram Methods 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 90
- 102000004127 Cytokines Human genes 0.000 description 46
- 108090000695 Cytokines Proteins 0.000 description 46
- 230000014509 gene expression Effects 0.000 description 43
- 230000002526 effect on cardiovascular system Effects 0.000 description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 201000010099 disease Diseases 0.000 description 33
- 238000009826 distribution Methods 0.000 description 33
- 102100024598 Tumor necrosis factor ligand superfamily member 10 Human genes 0.000 description 30
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 30
- 241000282414 Homo sapiens Species 0.000 description 27
- 238000012360 testing method Methods 0.000 description 26
- 206010061218 Inflammation Diseases 0.000 description 24
- 230000004054 inflammatory process Effects 0.000 description 24
- 239000000523 sample Substances 0.000 description 22
- 238000005259 measurement Methods 0.000 description 21
- 230000002861 ventricular Effects 0.000 description 21
- 102100030710 NAD-dependent protein deacetylase sirtuin-3, mitochondrial Human genes 0.000 description 19
- 238000003556 assay Methods 0.000 description 19
- 108091005770 SIRT3 Proteins 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 210000002889 endothelial cell Anatomy 0.000 description 17
- 230000036541 health Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000010410 layer Substances 0.000 description 15
- 208000024891 symptom Diseases 0.000 description 15
- 102000019034 Chemokines Human genes 0.000 description 14
- 108010012236 Chemokines Proteins 0.000 description 14
- -1 Mip-1α Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000000872 buffer Substances 0.000 description 13
- 238000002790 cross-validation Methods 0.000 description 13
- 210000000987 immune system Anatomy 0.000 description 13
- 210000002865 immune cell Anatomy 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 11
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 11
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 11
- 208000024172 Cardiovascular disease Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000002503 metabolic effect Effects 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 102000004889 Interleukin-6 Human genes 0.000 description 8
- 108090001005 Interleukin-6 Proteins 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 8
- 210000004413 cardiac myocyte Anatomy 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 210000003038 endothelium Anatomy 0.000 description 7
- 229940100601 interleukin-6 Drugs 0.000 description 7
- 210000005259 peripheral blood Anatomy 0.000 description 7
- 239000011886 peripheral blood Substances 0.000 description 7
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 206010003210 Arteriosclerosis Diseases 0.000 description 6
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 6
- 208000006029 Cardiomegaly Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108010004729 Phycoerythrin Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 231100000517 death Toxicity 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000003205 diastolic effect Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000007166 healthy aging Effects 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 238000000513 principal component analysis Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000611 regression analysis Methods 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 230000002485 urinary effect Effects 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 5
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 238000013528 artificial neural network Methods 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 210000003917 human chromosome Anatomy 0.000 description 5
- 238000002493 microarray Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 4
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000003293 cardioprotective effect Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000003828 downregulation Effects 0.000 description 4
- 230000007717 exclusion Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000013394 immunophenotyping Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 229910052741 iridium Inorganic materials 0.000 description 4
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000002438 mitochondrial effect Effects 0.000 description 4
- 210000004115 mitral valve Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102100026720 Interferon beta Human genes 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 102100026019 Interleukin-6 Human genes 0.000 description 3
- 108010002586 Interleukin-7 Proteins 0.000 description 3
- 102100021592 Interleukin-7 Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 230000010343 cardiac dilation Effects 0.000 description 3
- 230000004706 cardiovascular dysfunction Effects 0.000 description 3
- 230000009084 cardiovascular function Effects 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 230000019522 cellular metabolic process Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 210000001105 femoral artery Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000005291 magnetic effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 102000007863 pattern recognition receptors Human genes 0.000 description 3
- 108010089193 pattern recognition receptors Proteins 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Natural products C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 description 2
- 108010061300 CXCR3 Receptors Proteins 0.000 description 2
- 102000011963 CXCR3 Receptors Human genes 0.000 description 2
- 102000009410 Chemokine receptor Human genes 0.000 description 2
- 108050000299 Chemokine receptor Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 2
- 239000012625 DNA intercalator Substances 0.000 description 2
- 206010013012 Dilatation ventricular Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 208000031448 Genomic Instability Diseases 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 2
- 102000018653 Long-Chain Acyl-CoA Dehydrogenase Human genes 0.000 description 2
- 108010027062 Long-Chain Acyl-CoA Dehydrogenase Proteins 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 208000031662 Noncommunicable disease Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 201000007902 Primary cutaneous amyloidosis Diseases 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 108010041218 Sirtuin 3 Proteins 0.000 description 2
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 2
- 208000033774 Ventricular Remodeling Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000004721 adaptive immunity Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000036996 cardiovascular health Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000031902 chemoattractant activity Effects 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000013135 deep learning Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 208000032625 disorder of ear Diseases 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000138 intercalating agent Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000012886 linear function Methods 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 238000012008 microflow imaging Methods 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 208000014670 posterior cortical atrophy Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000013515 script Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 208000037905 systemic hypertension Diseases 0.000 description 2
- 230000030968 tissue homeostasis Effects 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002917 Aortic valve sclerosis Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 101100457310 Arabidopsis thaliana MIP1A gene Proteins 0.000 description 1
- 101100457311 Arabidopsis thaliana MIP1B gene Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 101150116911 CCL3 gene Proteins 0.000 description 1
- 101150047126 CCL4 gene Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016937 Chemokine CXCL9 Human genes 0.000 description 1
- 108010014231 Chemokine CXCL9 Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101150089023 FASLG gene Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101100441523 Homo sapiens CXCL5 gene Proteins 0.000 description 1
- 101000978392 Homo sapiens Eotaxin Proteins 0.000 description 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 1
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
- 101000655540 Homo sapiens Protransforming growth factor alpha Proteins 0.000 description 1
- 101100477600 Homo sapiens SIRT3 gene Proteins 0.000 description 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 101150106931 IFNG gene Proteins 0.000 description 1
- 108091058560 IL8 Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 102100033454 Interleukin-17F Human genes 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 101710127797 Macrophage colony-stimulating factor 1 Proteins 0.000 description 1
- 101710091439 Major capsid protein 1 Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 208000010362 Protozoan Infections Diseases 0.000 description 1
- 102100032350 Protransforming growth factor alpha Human genes 0.000 description 1
- 206010037448 Pulmonary valve incompetence Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007156 Resistin Human genes 0.000 description 1
- 108010047909 Resistin Proteins 0.000 description 1
- 101150009937 SIRT3 gene Proteins 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102000000478 Sirtuin 3 Human genes 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000013584 assay control Substances 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000004004 carotid artery internal Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 210000003698 chordae tendineae Anatomy 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 235000020645 curcumin supplement Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021045 dietary change Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000550 effect on aging Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000009429 electrical wiring Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 230000013764 eosinophil chemotaxis Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- 229940013317 fish oils Drugs 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000003633 gene expression assay Methods 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000010262 intracellular communication Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000012562 intraclass correlation Methods 0.000 description 1
- 238000010988 intraclass correlation coefficient Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012083 mass cytometry Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000003818 metabolic dysfunction Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000006677 mitochondrial metabolism Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000581 natural killer T-cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- VYNDHICBIRRPFP-UHFFFAOYSA-N pacific blue Chemical compound FC1=C(O)C(F)=C2OC(=O)C(C(=O)O)=CC2=C1 VYNDHICBIRRPFP-UHFFFAOYSA-N 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007111 proteostasis Effects 0.000 description 1
- 201000010298 pulmonary valve insufficiency Diseases 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000023895 stem cell maintenance Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013520 translational research Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000000596 ventricular septum Anatomy 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 235000012794 white bread Nutrition 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5406—IL-4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5409—IL-5
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5415—Leukaemia inhibitory factor [LIF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/545—IL-1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/56—IFN-alpha
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
[0001]本発明は、国立衛生研究所によって授与された契約番号AI057229及びAI090019の下の政府の支援で行われた。政府は、本発明に特定の権利を有する。
[0030]値の範囲が提供される場合、その範囲の上下限に挟まれる各値も、文脈に別段の明確な指図がない限り下限の単位の10分の1まで、特に開示されるものと理解される。記載される任意の値の間にあるより小さいそれぞれの範囲又は記載される範囲に挟まれる値及び記載される他の任意の値又は記載される範囲に挟まれる値は、本発明に包含される。これらのより小さい範囲の上下限は、その範囲内にそれぞれ独立に含まれても又は除外されてもよく、いずれか、いずれでもない又は両方の限度がより小さい範囲に含まれる各範囲も本発明に包含され、記載された範囲において特に除外される任意の限度に従属する。記載される範囲が限度の一方又は両方を含む場合、含まれる限度のいずれか一方又は両方を除外した範囲も、本発明に含まれる。
処置
[0060]対象由来サンプル中のCXCL9、TRAIL、IFNG、EOTAXIN及びGROAからなる群から選択されるタンパク質のうち2つ以上の量を測定する工程と、タンパク質の重み付き量に基づいて対象のSCIを算出する工程とを含む、対象の全身性慢性炎症加齢(SCI)を測定する方法を提供した。このように測定されるSCIに基づいて、対象は、全身性慢性炎症加齢を減少させる公知の方法(1)抗炎症薬(例えば、アスピリン、イブプロフェン及びナプロキセンなどのNSAID)又は副腎皮質ステロイドがあるがこれに限定されない薬物処置、(2)魚油、リポ酸及びクルクミン、又はショウガ、ニンニク及び唐辛子などのスパイスがあるがこれに限定されない栄養補給食品若しくは栄養補助剤、(3)オリーブ油、葉物野菜(例えば、ケール及びホウレンソウ)、トマト、脂肪が多い魚(例えば、サケ、イワシ及びサバ)、木の実及び果物(例えば、サクランボ、ブルーベリー及びオレンジ)など酸化防止剤及びポリフェノールが多い食物の摂取の増大並びに/又は精製した炭水化物(例えば、白パン及びペーストリー)、揚げ物、赤身肉及び加工肉など炎症を増大させ得る食物の摂取の低下があるがこれに限定されない食事の変更、(4)喫煙及びアルコール摂取を排除又は減少、健康な体重の維持、並びにストレスレベルの減少があるがこれに限定されない生活様式変更、のいずれかを単独で又は組み合わせて処置されてもよい。
キット
[0061]上述の対象の方法を実践するための試薬を含有するキットも本開示によって提供される。対象のキットは、上述した成分のいずれかを1つ又は複数含有する。一部の実施形態において、キットは、例えば、CXCL9に特異的に結合する捕捉薬剤、TRAILに特異的に結合する捕捉薬剤、IFNGに特異的に結合する捕捉薬剤、EOTAXINに特異的に結合する捕捉薬剤、GROAに特異的に結合する捕捉薬剤のうち2つ以上(例えば、3、4個又は全部)を含んでもよい。任意の実施形態において、捕捉薬剤は抗体であり得る。一部の実施形態において、各タンパク質について、キットは一次抗体及び二次抗体を含有してもよく、一次及び二次抗体は、タンパク質の異なる部分に結合する。一部の実施形態において、一次抗体は色分けされたビーズに連結されてもよく、二次抗体は標識、例えば、ビオチン化されてもよい。抗体は、アレイ形態であり得る。
[0063]上述の成分に加えて、対象のキットは、キットの成分を使用して対象の方法を実践するための説明書、即ち、サンプル分析の説明書を更に含んでもよい。対象の方法を実践する説明書は、適切な記録媒体上に一般に記録される。例えば、説明書は、紙又はプラスチック、等などの基材に印刷されてもよい。従って、説明書は、添付文書としてキット内、キットの容器又はその成分のラベル(即ち、包装又は個包装に関連する)、等に存在してもよい。他の実施形態において、説明書は適切なコンピュータ読み込み可能な格納媒体上に存在する電子格納データファイルとして存在する。更に他の実施形態において、実在の説明書はキット内に存在しないが、インターネットによるなど、遠隔ソースから説明書を得る手段が提供される。本実施形態の例は、説明書を見ることができる及び/又は説明書をダウンロードできるウェブアドレスを含むキットである。説明書と同様に、説明書を得る手段は適切な基材上に記録されている。
実施例1
材料及び方法
実験モデル及び対象の詳細
[0068]1000 Immunomes研究コホート:1KIPは、老化及び予防接種の研究(N=605)(Blazkovaら、2017年;Brodinら、2015年;Furmanら、2017年;Furmanら、2014年;Furmanら、2013年;Furmanら、2015年;Priceら、2013年;Roskinら、2015年;Shen−Orrら、2016年;Wangら、2014年)及び慢性疲労症候群の独立した研究(Montoyaら、2017年)のために2007年〜2016年にスタンフォード大学で募集した1001名の通院個人(男性339名及び女性662名)で構成され、参加者の対照組みからのデータ(N=396)だけを利用した。
方法の詳細
[0076]心血管表現型検査:心血管年齢は、3つのパラメータを使用して評価された(1)大動脈脈波速度(PWV)、血管硬化の尺度、(2)相対的壁厚(RWT)、心室再形成の尺度、及び(3)拡張早期僧帽弁輪運動速度(e’)、心室弛緩の尺度。加えて、拡張終期充満圧の代替マーカーである、初期僧帽弁流入血流速度(E)とe’の比(Naguehら、2009年;Redfieldら、2005年)が、測定された。
定量化及び統計分析
[0089]免疫特徴の分布:入力データは、血清タンパク質マイクロフローイメージング(MFI)及び細胞亜集団頻度データで構成された。データを、先に対数変換し、次いで、6つの異なる分布(正規、ラプラス、ログ正規、ログラプラス、ガンマ、ログガンマ)を、最尤推定(MLE)を使用して各入力特徴に当てはめた。各特徴について最良の分布を同定するために、5分割交差検定を、各分布について実行した。t検定p値を、正規分布と他の分布の間で5分割検定推定に対して算出した。
θをGAEの全てのパラメータの組であるとすると、訓練目的は
データ及びソフトウェア有効性
[0101]データ有効性:Stanford Aging and Vaccination研究の細胞亜集団、免疫タンパク質及び細胞シグナル伝達データは、以下の研究ID SDY311(サイトカイン、ホスホフローアッセイ及びCyTOF表面表現型検査)、SDY312(サイトカイン、ホスホフローアッセイ及びフローサイトメトリー表面表現型検査)、SDY314(フローサイトメトリー表面表現型検査)、SDY315(サイトカイン、ホスホフローアッセイ及びCyTOF表面表現型検査)及びSDY478(サイトカイン及びCyTOF表面表現型検査)の下でImmPort Bioinformatics Repository上で一般公開されている。
慢性疲労症候群対照サンプルの遺伝子発現データは、下のGene Expression Omnibus(GEO)上で利用可能である。
結果
1000イムノームプロジェクトの研究設計
[0102]2007年〜2016年の間、年齢8から>89歳の通院対象(N=1001)(男性339名及び女性662名)を、老化及び予防接種の経時的研究(Blazkovaら、2017年;Brodinら、2015年;Furmanら、2017年;Furmanら、2014年;Furmanら、2013年;Furmanら、2015年;Priceら、2013年;Roskinら、2015年;Shen−Orrら、2016年;Wangら、2014年)及び健康な対照だけが含まれる慢性疲労症候群(Montoyaら、2017年)の独立した研究のためにスタンフォード大学(1000 Immunomes Project;1KIP)で募集した。選択及び除外基準は、STAR Methodsセクションの下に見ることができる。1KIPの全てのサンプルについて、深層免疫表現型検査を、Stanford Human Immune Monitoring Center(HIMC)で行い、末梢血標本を厳密に標準化した手順を使用して処理及び分析した(Maeckerら、2012年)。全血を利用して全ゲノムのトランスクリプトームを分析し(N=394);血清サンプルを得、使用して、タンパク質(合計50種のサイトカイン、ケモカイン及び成長因子を含む)の含有量を決定し(N=1001)、サイトメガロウイルス陽性(N=748)、免疫系変動の主要決定因子を血清学的に評価した(Brodinら、2015年;Furmanら、2015年)。末梢血単核細胞又は全血サンプルを使用して、細胞表現型及び頻度を決定し(N=935)、様々なサイトカイン刺激に対するin vitro細胞応答を調査した(N=818)。拡張臨床的報告書形式を、231名が男性及び386名が女性である617/1001名の対象から収集した(図1及び表1)。
[0104]健康の免疫「測定基準」を見いだす目的で、末梢血からの50種の循環タンパク質のレベル及び25種の主要な免疫細胞の頻度の分布を特徴付けた。分布は、研究した集団における特定の免疫形質の観察した出現頻度を記載するので、サンプルの重要な統計的特徴である。そのため、集団研究において広く使用されている確率分布の強力な推定量である最尤推定(MLE)法を使用して、各免疫特徴について6つの異なる分布:正規、ラプラス、ログ正規、ログラプラス、ガンマ及びログガンマを当てはめた(Johansen及びJuselius、1990年)。各免疫特徴の分布を最もよく説明するモデルを同定するために、正規と各特徴の分布間のMLE検定に対して5分割交差検定を実行した。この方法によって、P値を得、ヌルモデルに対する各免疫特徴分布を決定した(方法を参照のこと)。
免疫型の同定
[0107]細胞は、免疫系の量子であり、それゆえ、免疫細胞の割合及び活性は、免疫応答の開始及び予後、並びに系を恒常性に戻す解決能力を統制する。類似の免疫構成を共有する個人のクラスターを同定し、健康対疾患状態にこれを更に関連付けるために、935/1001名の対象から入手可能な細胞割合データを利用した。データは、質量サイトメトリーを使用して分析した721名のサンプル及びフローサイトメトリーを使用して分析した213名からなった(図15)。比較的大きなサンプルサイズの研究を活用することによって統計的検出力を最大化するために、両方のコホートにおいて一般に測定される細胞型の合計数を使用した。これは合計25個の細胞亜集団を生じ、その亜集団を、全935名の対象において一貫して測定した。データを正規化し、各特徴とデータソースの間の線形相関がゼロであるようにデータソースに対して回帰分析を行った(方法を参照のこと)。クラスタリング分析を、処理したデータに対する凝集クラスタリングを使用して行った。有意なクラスターを同定するために、ギャップ統計を使用した。ギャップ統計は、形成されたクラスターのクラスター内分散を比較し、それに対して「ヌル」分布を作成するためにブートストラップを利用するよく確立された方法であり(Tibshiraniら、2001年)、従って、各クラスターの統計的有意性の推定が可能になる。1000個のブートストラップを使用した結果、クラスターの最善の数は16個であった。元データに対する主成分分析(PCA)は、最初の3つのPCAがこれらクラスターの大部分を明らかにすることを示した。一部のクラスターは、別の投射において異なる可能性があったので最初の3つのPCAによってよく分離されなかった。
免疫型の免疫特徴付け
[0113]炎症レベル及び急性抗原接種に応答する免疫細胞の能力に関して免疫型を特徴付けるために、1001名の対象全員に利用可能な免疫タンパク質データ(50種のサイトカイン、ケモカイン及び成長因子)及び合計818名の対象に利用可能なサイトカイン刺激データ(84個の異なるサイトカイン−細胞−リンタンパク質の組合せ)に対するex vivoシグナル応答を使用した(表1)。分析は、マイクロアレイの予測分析(PAM)(Tibshiraniら、2002年)、最短収縮重心法を使用して免疫型全体で各免疫特徴のレベルを比較する統計的技術、を使用して計算した(方法を参照のこと)。本方法は、標準的な最短重心分類に1つの重要な修飾を行い;全ての免疫型について免疫型重心のそれぞれを全体の重心の方へ「収縮」させ、ノイズが多い特徴の効果を減少させることで分類子をより正確にする(方法を参照のこと)。大部分の場合、各免疫型は、相関するレベルの免疫タンパク質を呈し、即ち、所与の免疫型の場合、サイトカインが他の全ての免疫型に対してより高い又はより低いレベルで見られ、大部分のサイトカインは同じ方向に変化する傾向があり、類似の現象がシグナル応答について観察された。循環免疫タンパク質のレベルが低い、及びその逆の免疫型においてより有力な応答が観察され、従って、このことは、炎症マーカーが、免疫抗原接種に対する急性応答の負の予測因子であることを示すFourati Sら(2016年)(Fouratiら、2016年)、Shen−Orrら(2016年)(Shen−Orrら、2016年)及びVerschoor CPら(2017年)(Verschoorら、2017年)の最近のデータと一致して、急性免疫抗原接種に協調した応答及び全身性炎症の負の効果を示す。
免疫型の臨床的特徴付け
[0116]免疫型の臨床的影響を決定するために、免疫型3、4、7、8、10、12、13、14、15及び16に属する527/617名の参加者から一貫して得られた臨床質問表(合計して53個の疾患特徴)(図16)から、各免疫型を疾患状態と関連させる地図を得た(図2)。有意な相関を、そのような疾患特徴の合計16個について観察した(年齢、性別、CMV及びBMI調整後、p<0.05)。予想通り、がん並びに骨、筋肉及び関節を含めた他の加齢に伴う症状などの低い発生率が、他の全ての免疫型と比較して免疫型3(平均年齢23歳、年齢範囲8〜52歳)で観察された。しかしながら、免疫型8(平均年齢23歳、年齢範囲12〜79歳)の対象における、がん及び高血圧の低い発生率の呈示にもかかわらず、陽性相関が、筋肉及び関節痛などの筋骨格症状並びに泌尿器系疾患に見られた(図2)。興味深いことに、大部分が若年対象で構成されるが高齢対象の小集団と免疫プロファイルを共有する免疫型12は、生殖器及び生殖系、並びに胃腸、内分泌代謝、皮膚病及び泌尿器系に関連するものを含めた疾患から大部分保護された。これらの観察にもかかわらず、免疫型12の対象は、平均して、他の全ての免疫型と比較して筋肉及び関節痛の発生率が高く(P<0.001)、がん発生率は低いが、有意であった(R=0.09、P<0.05)。
SCIの構築
[0119]特に心臓血管疾患の分野において、高齢に関連する様々な疾患の発症における低悪性度の全身性及び慢性炎症のますます認識された効果(Furmanら、2017年;Ridkerら、2017年)を考慮すれば、個人の炎症性レベルを要約し得る測定基準を構築することが重要であった。この型の炎症は、組織損傷、代謝性機能不全及び環境的負荷への曝露(「エクスポソーム」とまとめて命名された)に応答する不適応な反応として起こると考えられる(Goldberg及びDixit、2015年;Kotas及びMedzhitov、2015年)。従ってその炎症は、急性炎症応答とは異なって感染症又は外傷に応答して起こり、高悪性度で自己制限的なものである。急性炎症の場合、多くの標準的なマーカーが検証されており、これらには、急性期タンパク質、C反応性タンパク質並びに、とりわけ、IL−1β、IL−6及びTNF−αなど有力な炎症性サイトカインがある。しかしながら、老人性慢性炎症に標準的なバイオマーカーは存在しない(Franceschiら、2017年;Morrisette−Thomasら、2014年)。従って、サイトカインネットワークの非線形構造を簡潔に表すために不偏な手法を企てた。そのために、ガイド付き自動エンコーダ(GAE)と呼ばれる深層学習方法を、合計1001名の対象からの、合計50種のサイトカイン、ケモカイン及び成長因子を包含する循環免疫タンパク質データに適用した。
SCIは、同時罹患数及び心血管老化と相関する
[0122]老人性病変に対する慢性炎症の効果に関して更なる洞察を獲得するために、異なる生理学系を表し、高齢に一般に関連する10個の疾患項目、及び疾患の和(同時罹患数)とSCIの間で計算した回帰分析を選択した。分析した項目は、がん、心血管、呼吸、胃腸、泌尿器学、神経、内分泌代謝、筋骨格、生殖器生殖及び精神医学的であった。これら全ての疾患特徴は二者択一であった。これらの分析の場合、調整を、年齢、BMI、性別、CMV及び高コレステロール(これも二者択一のカテゴリーである)(図3A)について行い、老人性病変の病因におけるこれら変数のそれぞれの報告されている効果を考慮した。複合試験(順列検定による)を制御した後に、研究した集団におけるSCIと同時罹患数の間の有意な相関(N=527、P<0.0001)が、観察された(図3A)。
CXCL9は、SCIの重要な成分であり、健康な成人において心血管老化と相関する
[0126]炎症が心血管機能不全に関連する潜在的機序について更なる洞察を獲得するために、どの因子がSCIに最も寄与するか分析することが目標であった。そのために、SCIを、最も可変的なヤコビアン(SCIの一階偏導関数)を計算することによって単一の免疫タンパク質の特徴に分解した。SCIに対して正及び負の要因(図5)が、見つかった。最も可変的なヤコビアンの上位15個は、CXCL9、EOTAXIN、Mip−1α、LEPTIN、IL−1β、IL−5、IFN−α及びIL−4(正の要因)並びにTRAIL、IFN−β、GRO−α、IL−2、TGF−α、PAI−1及びLIF(負の要因)であった(図5)。
老化内皮細胞は高レベルのCXCL9を発現し、これは心臓保護SIRT3のmRNA下方調節を誘導する
[0130]長期にわたる証拠は、高血圧及び動脈硬化の病因における内皮の決定的な役割を示唆し、より最近の仕事は、組織再形成及び心臓肥大など心血管老化のいっそう進行した徴候がしばしば先行し、老化した内皮の機能異常によって開始され得ることも示した(Castellon及びBogdanova、2016年;Harveyら、2015年;Kamoら、2015年)。この工程におけるCXCL9の役割を研究するために、5名のドナーから得たヒト線維芽細胞を、Yamanaka因子(Takahashi及びYamanaka、2006年)を使用して多能性幹細胞(hiPSC)表現型に誘導し、次いで、その細胞を内皮細胞(hiPSC−EC)に分化させた。老化による効果をモデル化するために、hiPSC−ECを、以前に記載されている(Huら、2016年)明確に定義された条件下で、示した通り何度も継代し(図7A)、CXCL9及びSIRT3のmRNA発現レベルを測定した。サーチュイン3は、老化中のミトコンドリア恒常性、幹細胞及び組織の維持に関係する心臓保護特性を持つ重要な脱アセチル化酵素であり、心血管健康並びに長命の維持において食事及び運動の有益な効果と結びつけられる(Bonkowski及びSinclair、2016年;Luら、2016年)。
健康な老化免疫型の対象は、不健康な老化免疫型の対象と比較して死亡率が低く、13歳若いSCI対実年齢の差がある
[0132]1KIPコホートの対象のサブセット(N=112)は、2007年に開始した長期的な老化の研究の一部であり(Furmanら、2017年;Shen−Orrら、2016年)1年毎に対象の人数が変わった。このサブグループからの合計18名の個人が、9年間の追跡調査の間に亡くなった。老人性免疫型HAiT及びUAiTと死亡率の関係を調査するために、年齢75歳及びそれ以上の対象(免疫応答における著しい修飾及び死亡リスクの上昇が公知である)を選択した。HAiT(免疫型14)の場合、合計23名の対象を選択し、そのうち2名(8.6%)が研究の間に死亡した。UAiT(免疫型13及び16の組合せ)の場合、合計50名の対象が、≧75歳のカテゴリーであり、そのうちの13名(26%)が研究中に死亡した(P=0.089、ピアソンのカイ二乗検定による)。全体として、死亡の大多数(13/18名、72%)はUAiT群からの対象に発生し、わずか2名(11%)がHAiT群からであった(図8A)。2名(11%)の死亡は免疫型15からの対象であり、更なる1名の死亡は、免疫表現型検査データがその対象に利用できなかったので、どの免疫型にも分類できなかった(図8A)。
考察
[0134]GAEを使用して得られる全身性慢性炎症加齢は、年齢、高コレステロール、性別及びBMIに対する調整後に同時罹患数と有意に相関した。これは、ヒト健康対疾患のためのこの免疫「測定基準」をコンパニオンラボ試験として使用して、患者の炎症性状況について医師に情報を提供し得ることを示唆している。心臓血管機能を徹底的に監視した40名の高齢対象のより小さな群において、SCIが、高血圧、動脈硬化、より一般にはメタボリックシンドロームなどの老人性同時罹患数の後期臨床段階であることが公知の動脈硬化及び心臓肥大によって測定される心血管老化も予測したという事実は驚くことではない。しかし、目ざましい発見は、疾患の徴候がない97名の非常に健康な高齢個人のより大きなコホートにおいて、SCIの主要な要因であるCXCL9が動脈硬化及び心臓肥大の不顕性レベルと正に相関したことであった。これらの結果は、SCIが、不顕性心血管機能異常の可能性があるものに対する初期分子マーカーとしても使用され得ることを強く示唆している。
参考文献
Ahn, B.H., Kim, H.S., Song, S., Lee, I.H., Liu, J., Vassilopoulos, A., Deng, C.X., and Finkel, T. (2008). A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America 105, 14447-14452.
Alrob, O.A., Sankaralingam, S., Ma, C., Wagg, C.S., Fillmore, N., Jaswal, J.S., Sack, M.N., Lehner, R., Gupta, M.P., Michelakis, E.D., et al. (2014). Obesity-induced lysine acetylation increases cardiac fatty acid oxidation and impairs insulin signalling. Cardiovascular research 103, 485-497.
Altara, R., Gu, Y.M., Struijker-Boudier, H.A., Thijs, L., Staessen, J.A., and Blankesteijn, W.M. (2015). Left Ventricular Dysfunction and CXCR3 Ligands in Hypertension: From Animal Experiments to a Population-Based Pilot Study. PloS one 10, e0141394.
Bektas, A., Schurman, S.H., Sen, R., and Ferrucci, L. (2017). Human T cell immunosenescence and inflammation in aging. Journal of leukocyte biology 102, 977-988.
Bellizzi, D., Rose, G., Cavalcante, P., Covello, G., Dato, S., De Rango, F., Greco, V., Maggiolini, M., Feraco, E., Mari, V., et al. (2005). A novel VNTR enhancer within the SIRT3 gene, a human homologue of SIR2, is associated with survival at oldest ages. Genomics 85, 258-263.
Bengio, Y. (2009). Learning Deep Architectures for AI. Foundations and Trends in Machine Learning: 2, 1-127.
Blazkova, J., Gupta, S., Liu, Y., Gaudilliere, B., Ganio, E.A., Bolen, C.R., Saar-Dover, R., Fragiadakis, G.K., Angst, M.S., Hasni, S., et al. (2017). Multicenter Systems Analysis of Human Blood Reveals Immature Neutrophils in Males and During Pregnancy. Journal of immunology 198, 2479-2488.
Bonkowski, M.S., and Sinclair, D.A. (2016). Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds. Nature reviews Molecular cell biology 17, 679-690.
Brodin, P., Jojic, V., Gao, T., Bhattacharya, S., Angel, C.J., Furman, D., Shen-Orr, S., Dekker, C.L., Swan, G.E., Butte, A.J., et al. (2015). Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37-47.
Castellon, X., and Bogdanova, V. (2016). Chronic Inflammatory Diseases and Endothelial Dysfunction. Aging and disease 7, 81-89.
Cavadas, C., Aveleira, C.A., Souza, G.F., and Velloso, L.A. (2016). The pathophysiology of defective proteostasis in the hypothalamus - from obesity to ageing. Nature reviews Endocrinology 12, 723-733.
Chen, T., Liu, J., Li, N., Wang, S., Liu, H., Li, J., Zhang, Y., and Bu, P. (2015). Mouse SIRT3 attenuates hypertrophy-related lipid accumulation in the heart through the deacetylation of LCAD. PloS one10, e0118909.
Crusz, S.M., and Balkwill, F.R. (2015). Inflammation and cancer: advances and new agents. Nature reviews Clinical oncology12, 584-596.
Dai, H., Leeder, J.S., and Cui, Y. (2014). A modified generalized Fisher method for combining probabilities from dependent tests. Frontiers in genetics 5, 32.
Desponds, J., Mora, T., and Walczak, A.M. (2016). Fluctuating fitness shapes the clone-size distribution of immune repertoires. Proceedings of the National Academy of Sciences of the United States of America 113, 274-279.
Efeyan, A., Comb, W.C., and Sabatini, D.M. (2015). Nutrient-sensing mechanisms and pathways. Nature 517, 302-310.
Eming, S.A., Wynn, T.A., and Martin, P. (2017). Inflammation and metabolism in tissue repair and regeneration. Science 356, 1026-1030.
Epelman, S., Liu, P.P., and Mann, D.L. (2015). Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nature reviews Immunology 15, 117-129.
Esensten, J.H., Helou, Y.A., Chopra, G., Weiss, A., and Bluestone, J.A. (2016). CD28 Costimulation: From Mechanism to Therapy. Immunity 44, 973-988.
Fourati, S., Cristescu, R., Loboda, A., Talla, A., Filali, A., Railkar, R., Schaeffer, A.K., Favre, D., Gagnon, D., Peretz, Y., et al. (2016). Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nature communications 7, 10369.
Franceschi, C., and Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. The journals of gerontology Series A, Biological sciences and medical sciences 69 Suppl 1, S4-9.
Franceschi, C., Garagnani, P., Vitale, G., Capri, M., and Salvioli, S. (2017). Inflammaging and 'Garb-aging'. Trends in endocrinology and metabolism: TEM 28, 199-212.
Furman, D., Chang, J., Lartigue, L., Bolen, C.R., Haddad, F., Gaudilliere, B., Ganio, E.A., Fragiadakis, G.K., Spitzer, M.H., Douchet, I., et al. (2017). Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nature medicine 23, 174-184.
Furman, D., Hejblum, B.P., Simon, N., Jojic, V., Dekker, C.L., Thiebaut, R., Tibshirani, R.J., and Davis, M.M. (2014). Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proceedings of the National Academy of Sciences of the United States of America 111, 869-874.
Furman, D., Jojic, V., Kidd, B., Shen-Orr, S., Price, J., Jarrell, J., Tse, T., Huang, H., Lund, P., Maecker, H.T., et al.(2013). Apoptosis and other immune biomarkers predict influenza vaccine responsiveness. Molecular systems biology9, 659.
Furman, D., Jojic, V., Sharma, S., Shen-Orr, S.S., Angel, C.J., Onengut-Gumuscu, S., Kidd, B.A., Maecker, H.T., Concannon, P., Dekker, C.L., et al. (2015). Cytomegalovirus infection enhances the immune response to influenza. Science translational medicine 7, 281ra243.
Goldberg, E.L., and Dixit, V.D. (2015). Drivers of age-related inflammation and strategies for healthspan extension. Immunological reviews 265, 63-74.
Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.
Gu, M., Shao, N.Y., Sa, S., Li, D., Termglinchan, V., Ameen, M., Karakikes, I., Sosa, G., Grubert, F., Lee, J., et al.(2017). Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers. Cell stem cell 20, 490-504 e495.
Guo, X., Yan, F., Li, J., Zhang, C., and Bu, P. (2017). SIRT3 attenuates AngII-induced cardiac fibrosis by inhibiting myofibroblasts transdifferentiation via STAT3-NFATc2 pathway. American journal of translational research 9, 3258-3269.
Haralambieva, I.H., Zimmermann, M.T., Ovsyannikova, I.G., Grill, D.E., Oberg, A.L., Kennedy, R.B., and Poland, G.A. (2016). Whole Transcriptome Profiling Identifies CD93 and Other Plasma Cell Survival Factor Genes Associated with Measles-Specific Antibody Response after Vaccination. PloS one 11, e0160970.
Harvey, A., Montezano, A.C., and Touyz, R.M. (2015). Vascular biology of ageing-Implications in hypertension. Journal of molecular and cellular cardiology 83, 112-121.
Hirschey, M.D., Shimazu, T., Goetzman, E., Jing, E., Schwer, B., Lombard, D.B., Grueter, C.A., Harris, C., Biddinger, S., Ilkayeva, O.R., et al. (2010). SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature464, 121-125.
Hu, S., Zhao, M.T., Jahanbani, F., Shao, N.Y., Lee, W.H., Chen, H., Snyder, M.P., and Wu, J.C. (2016). Effects of cellular origin on differentiation of human induced pluripotent stem cell-derived endothelial cells. JCI insight 1.
Hunter, R.L., Dragicevic, N., Seifert, K., Choi, D.Y., Liu, M., Kim, H.C., Cass, W.A., Sullivan, P.G., and Bing, G. (2007). Inflammation induces mitochondrial dysfunction and dopaminergic neurodegeneration in the nigrostriatal system. Journal of neurochemistry 100, 1375-1386.
Huynen, M.A., and van Nimwegen, E. (1998). The frequency distribution of gene family sizes in complete genomes. Molecular biology and evolution 15, 583-589.
Johansen, S., and Juselius, K. (1990). MAXIMUM LIKELIHOOD ESTIMATION AND INFERENCE ON COINTEGRATION - WITH APPLICATIONS TO THE DEMAND FOR MONEY. Oxford Bulletin of Economics and Statistics 52, 169-210.
Jurk, D., Wilson, C., Passos, J.F., Oakley, F., Correia-Melo, C., Greaves, L., Saretzki, G., Fox, C., Lawless, C., Anderson, R., et al. (2014). Chronic inflammation induces telomere dysfunction and accelerates ageing in mice. Nature communications 2, 4172.
Kaczorowski, K.J., Shekhar, K., Nkulikiyimfura, D., Dekker, C.L., Maecker, H., Davis, M.M., Chakraborty, A.K., and Brodin, P. (2017). Continuous immunotypes describe human immune variation and predict diverse responses. Proceedings of the National Academy of Sciences of the United States of America 114, E6097-E6106.
Kamo, T., Akazawa, H., and Komuro, I. (2015). Cardiac nonmyocytes in the hub of cardiac hypertrophy. Circulation research117, 89-98.
Kingma, D., and Jimmy, B. (2014). Adam: A method for stochastic optimization. arXiv 1412.6980.
Kotas, M.E., and Medzhitov, R. (2015). Homeostasis, inflammation, and disease susceptibility. Cell 160, 816-827.
Lang, R.M., Bierig, M., Devereux, R.B., Flachskampf, F.A., Foster, E., Pellikka, P.A., Picard, M.H., Roman, M.J., Seward, J., Shanewise, J.S., et al. (2005). Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 18, 1440-1463.
Larbi, A., and Fulop, T. (2014). From "truly naive" to "exhausted senescent" T cells: when markers predict functionality. Cytometry Part A : the journal of the International Society for Analytical Cytology 85, 25-35.
Lasry, A., and Ben-Neriah, Y. (2015). Senescence-associated inflammatory responses: aging and cancer perspectives. Trends in immunology 36, 217-228.
Li, S., Rouphael, N., Duraisingham, S., Romero-Steiner, S., Presnell, S., Davis, C., Schmidt, D.S., Johnson, S.E., Milton, A., Rajam, G., et al. (2014). Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nature immunology 15, 195-204.
Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine, L.B., Azarin, S.M., Raval, K.K., Zhang, J., Kamp, T.J., and Palecek, S.P. (2012). Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proceedings of the National Academy of Sciences of the United States of America 109, E1848-1857.
Liu, C.H., Abrams, N.D., Carrick, D.M., Chander, P., Dwyer, J., Hamlet, M.R.J., Macchiarini, F., PrabhuDas, M., Shen, G.L., Tandon, P., et al. (2017). Biomarkers of chronic inflammation in disease development and prevention: challenges and opportunities. Nature immunology 18, 1175-1180.
Lopez-Otin, C., Blasco, M.A., Partridge, L., Serrano, M., and Kroemer, G. (2013). The hallmarks of aging. Cell 153, 1194-1217.
Lu, Y., Wang, Y.D., Wang, X.Y., Chen, H., Cai, Z.J., and Xiang, M.X. (2016). SIRT3 in cardiovascular diseases: Emerging roles and therapeutic implications. International journal of cardiology 220, 700-705.
Maecker, H.T., Lindstrom, T.M., Robinson, W.H., Utz, P.J., Hale, M., Boyd, S.D., Shen-Orr, S.S., and Fathman, C.G. (2012). New tools for classification and monitoring of autoimmune diseases. Nature reviews Rheumatology 8, 317-328.
Matsa, E., Burridge, P.W., Yu, K.H., Ahrens, J.H., Termglinchan, V., Wu, H., Liu, C., Shukla, P., Sayed, N., Churko, J.M., et al. (2016). Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. Cell stem cell 19, 311-325.
McKinney, E.F., Lee, J.C., Jayne, D.R., Lyons, P.A., and Smith, K.G. (2015). T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523, 612-616.
Medzhitov, R. (2008). Origin and physiological roles of inflammation. Nature 454, 428-435.
Mezzaroma, E., Toldo, S., Farkas, D., Seropian, I.M., Van Tassell, B.W., Salloum, F.N., Kannan, H.R., Menna, A.C., Voelkel, N.F., and Abbate, A. (2011). The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse. Proceedings of the National Academy of Sciences of the United States of America 108, 19725-19730.
Montoya, J.G., Holmes, T.H., Anderson, J.N., Maecker, H.T., Rosenberg-Hasson, Y., Valencia, I.J., Chu, L., Younger, J.W., Tato, C.M., and Davis, M.M. (2017). Cytokine signature associated with disease severity in chronic fatigue syndrome patients. Proceedings of the National Academy of Sciences of the United States of America 114, E7150-E7158.
Morrisette-Thomas, V., Cohen, A.A., Fulop, T., Riesco, E., Legault, V., Li, Q., Milot, E., Dusseault-Belanger, F., and Ferrucci, L. (2014). Inflamm-aging does not simply reflect increases in pro-inflammatory markers. Mechanisms of ageing and development 139, 49-57.
Nagueh, S.F., Appleton, C.P., Gillebert, T.C., Marino, P.N., Oh, J.K., Smiseth, O.A., Waggoner, A.D., Flachskampf, F.A., Pellikka, P.A., and Evangelisa, A. (2009). Recommendations for the evaluation of left ventricular diastolic function by echocardiography. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 10, 165-193.
Nakaya, H.I., Wrammert, J., Lee, E.K., Racioppi, L., Marie-Kunze, S., Haining, W.N., Means, A.R., Kasturi, S.P., Khan, N., Li, G.M., et al. (2011). Systems biology of vaccination for seasonal influenza in humans. Nature immunology 12, 786-795.
Nathan, C., and Cunningham-Bussel, A. (2013). Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nature reviews Immunology 13, 349-361.
Naumov, Y.N., Naumova, E.N., Hogan, K.T., Selin, L.K., and Gorski, J. (2003). A fractal clonotype distribution in the CD8+ memory T cell repertoire could optimize potential for immune responses. Journal of immunology 170, 3994-4001.
Nevers, T., Salvador, A.M., Grodecki-Pena, A., Knapp, A., Velazquez, F., Aronovitz, M., Kapur, N.K., Karas, R.H., Blanton, R.M., and Alcaide, P. (2015). Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure. Circulation Heart failure 8, 776-787.
Oh, J., Lee, Y.D., and Wagers, A.J. (2014a). Stem cell aging: mechanisms, regulators and therapeutic opportunities. Nature medicine 20, 870-880.
Oh, J.Z., Ravindran, R., Chassaing, B., Carvalho, F.A., Maddur, M.S., Bower, M., Hakimpour, P., Gill, K.P., Nakaya, H.I., Yarovinsky, F., et al. (2014b). TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 41, 478-492.
Possemato, R., Marks, K.M., Shaul, Y.D., Pacold, M.E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.K., Jang, H.G., Jha, A.K., et al. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476, 346-350.
Price, J.V., Jarrell, J.A., Furman, D., Kattah, N.H., Newell, E., Dekker, C.L., Davis, M.M., and Utz, P.J. (2013). Characterization of influenza vaccine immunogenicity using influenza antigen microarrays. PloS one 8, e64555.
Querec, T.D., Akondy, R.S., Lee, E.K., Cao, W., Nakaya, H.I., Teuwen, D., Pirani, A., Gernert, K., Deng, J., Marzolf, B., et al. (2009). Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nature immunology10, 116-125.
Redfield, M.M., Jacobsen, S.J., Borlaug, B.A., Rodeheffer, R.J., and Kass, D.A. (2005). Age- and gender-related ventricular-vascular stiffening: a community-based study. Circulation 112, 2254-2262.
Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S.D., et al. (2017). Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England journal of medicine 377, 1119-1131.
Rose, G., Dato, S., Altomare, K., Bellizzi, D., Garasto, S., Greco, V., Passarino, G., Feraco, E., Mari, V., Barbi, C., et al. (2003). Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly. Experimental gerontology 38, 1065-1070.
Roskin, K.M., Simchoni, N., Liu, Y., Lee, J.Y., Seo, K., Hoh, R.A., Pham, T., Park, J.H., Furman, D., Dekker, C.L., et al.(2015). IgH sequences in common variable immune deficiency reveal altered B cell development and selection. Science translational medicine 7, 302ra135.
Shen-Orr, S.S., and Furman, D. (2013). Variability in the immune system: of vaccine responses and immune states. Current opinion in immunology 25, 542-547.
Shen-Orr, S.S., Furman, D., Kidd, B.A., Hadad, F., Lovelace, P., Huang, Y.W., Rosenberg-Hasson, Y., Mackey, S., Grisar, F.A., Pickman, Y., et al. (2016). Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans. Cell systems 3, 374-384 e374.
Strindhall, J., Skog, M., Ernerudh, J., Bengner, M., Lofgren, S., Matussek, A., Nilsson, B.O., and Wikby, A. (2013). The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age 35, 985-991.
Subramanian, N., Torabi-Parizi, P., Gottschalk, R.A., Germain, R.N., and Dutta, B. (2015). Network representations of immune system complexity. Wiley interdisciplinary reviews Systems biology and medicine 7, 13-38.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676.
Thevaranjan, N., Puchta, A., Schulz, C., Naidoo, A., Szamosi, J.C., Verschoor, C.P., Loukov, D., Schenck, L.P., Jury, J., Foley, K.P., et al. (2017). Age-Associated Microbial Dysbiosis Promotes Intestinal Permeability, Systemic Inflammation, and Macrophage Dysfunction. Cell host & microbe 21, 455-466 e454.
Tibshirani, R., Hastie, T., Narasimhan, B., and Chu, G. (2002). Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proceedings of the National Academy of Sciences of the United States of America 99, 6567-6572.
Tibshirani, R.J., Guenther, W., and Hastie, T. (2001). Estimating the number of clusters in a data set via the gap statistic. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 63, 411-423.
Versari, D., Daghini, E., Virdis, A., Ghiadoni, L., and Taddei, S. (2009). Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes care 32 Suppl 2, S314-321.
Verschoor, C.P., Lelic, A., Parsons, R., Evelegh, C., Bramson, J.L., Johnstone, J., Loeb, M.B., and Bowdish, D.M.E. (2017). Serum C-Reactive Protein and Congestive Heart Failure as Significant Predictors of Herpes Zoster Vaccine Response in Elderly Nursing Home Residents. The Journal of infectious diseases 216, 191-197.
Wang, C., Liu, Y., Xu, L.T., Jackson, K.J., Roskin, K.M., Pham, T.D., Laserson, J., Marshall, E.L., Seo, K., Lee, J.Y., et al. (2014). Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires. Journal of immunology 192, 603-611.
Weinstein, J.A., Jiang, N., White, R.A., 3rd, Fisher, D.S., and Quake, S.R. (2009). High-throughput sequencing of the zebrafish antibody repertoire. Science 324, 807-810.
Weng, N.P., Akbar, A.N., and Goronzy, J. (2009). CD28(-) T cells: their role in the age-associated decline of immune function. Trends in immunology 30, 306-312.
Wiley, C.D., and Campisi, J. (2016). From Ancient Pathways to Aging Cells-Connecting Metabolism and Cellular Senescence. Cell metabolism 23, 1013-1021.
Zou, H.a.H., T. (2005). Regularization and variable selection via the elastic net. Journal of Royal Statistical Society, Series B 67, 301-320.
Claims (13)
- (a)対象由来サンプル中のCXCL9、TRAIL、IFNG、EOTAXIN及びGROAからなる群から選択されるタンパク質のうち2つ以上の量を測定する工程;及び
(b)前記2つ以上のタンパク質の重み付き量に基づいて前記対象のSCIスコアを算出する工程、
を含む、対象の全身性慢性炎症加齢(SCI)を評価する方法。 - 前記サンプルが血清である、請求項1に記載の方法。
- ガイド付き自動エンコーダアルゴリズムを使用して前記SCIスコアを算出する工程を含む、請求項1に記載の方法。
- 多重アッセイにおいて前記2つ以上のタンパク質の量を測定する工程を含む、請求項1に記載の方法。
- CXCL9及びEOTAXINの増大が、SCIと正に相関する、請求項1に記載の方法。
- TRAIL、IFNG及びGROAの減少が、SCIと負に相関する、請求項1に記載の方法。
- 実年齢に対して前記SCIスコアを調整する工程を含む、請求項1に記載の方法。
- 血中コレステロール、性別及びBMIからなる群の1つ又は複数のメンバーに対して前記SCIスコアを更に調整する工程を含む、請求項7に記載の方法。
- (a)前記対象由来サンプル中のCXCL9、TRAIL、IFNG、EOTAXIN及びGROAからなる群から選択されるタンパク質のうち2つ以上の重み付き量に基づいてSCIスコアを算出する工程;及び
(b)前記SCIスコアが前記対象の実年齢より大きい場合に、前記対象を処置してSCIを減少させる工程、
を含む、全身性慢性炎症加齢(SCI)を減少させる処置を必要とする対象を同定する方法。 - CXCL9、TRAIL、IFNG、EOTAXIN及びGROAからなる群から選択される異なるタンパク質に特異的に結合する2つ以上の捕捉薬剤、並びに使用説明書を含む、対象の前記全身性慢性炎症加齢(SCI)を測定するためのキット。
- 前記2つ以上の捕捉薬剤がモノクローナル抗体である、請求項10に記載のキット。
- 前記異なるタンパク質のそれぞれに結合する一次抗体及び二次抗体を含む、請求項10に記載のキット。
- 前記一次抗体が、着色されたビーズにそれぞれ連結され、前記二次抗体が、それぞれ標識される、請求項12に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862633539P | 2018-02-21 | 2018-02-21 | |
US62/633,539 | 2018-02-21 | ||
PCT/US2019/019047 WO2019165145A1 (en) | 2018-02-21 | 2019-02-21 | Method for measuring systemic chronic inflammaging |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021514479A true JP2021514479A (ja) | 2021-06-10 |
Family
ID=67686944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020567440A Pending JP2021514479A (ja) | 2018-02-21 | 2019-02-21 | 全身性慢性炎症加齢を測定する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210109109A1 (ja) |
EP (1) | EP3762506A4 (ja) |
JP (1) | JP2021514479A (ja) |
CN (1) | CN112136048A (ja) |
WO (1) | WO2019165145A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3977136A4 (en) * | 2019-05-24 | 2023-05-10 | Edifice Health, Inc. | PRECISION DRUGS FOR CANCER IMMUNOTHERAPY |
US11359011B2 (en) | 2019-08-07 | 2022-06-14 | Edifice Health, Inc. | Treatment and prevention of cardiovascular disease |
EP4058046A1 (en) * | 2019-11-12 | 2022-09-21 | Edifice Health, Inc. | A precision medicine method for immunotherapy |
US20210315921A1 (en) * | 2020-04-13 | 2021-10-14 | Edifice Health, Inc. | Compounds and Methods for Modifying iAge |
WO2022093763A1 (en) * | 2020-10-29 | 2022-05-05 | Edifice Health, Inc. | Methods and compositions for diagnosing and treating frailty |
WO2022177815A1 (en) * | 2021-02-19 | 2022-08-25 | Edifice Health, Inc. | MUCOSAL DELIVERY OF COMPOUNDS FOR MODIFYING iAGE |
WO2022187087A1 (en) * | 2021-03-04 | 2022-09-09 | Edifice Health, Inc. | Gene expression inflammatory age and its uses |
CN113229787A (zh) * | 2021-03-22 | 2021-08-10 | 安庆师范大学 | 基于脉搏信号形状特征的血管年龄估算及有效性评价方法 |
MX2024001124A (es) * | 2021-07-28 | 2024-03-05 | Quaker Oats Co | Metodo de reduccion de inflamacion cronica y sistemica relacionada con la edad. |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100124756A1 (en) * | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
JP2011067214A (ja) * | 2001-11-09 | 2011-04-07 | Source Precision Medicine Inc | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 |
WO2011094535A2 (en) * | 2010-01-28 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
US20120021414A1 (en) * | 2010-06-25 | 2012-01-26 | Howard Hughes Medical Institute | Diagnostic markers of immunosenescence and methods of use thereof |
US20120122717A1 (en) * | 2006-10-06 | 2012-05-17 | Nestec S.A. | Composition and multiplex assays for measuring biological mediators of physiological health |
US20150126408A1 (en) * | 2007-08-20 | 2015-05-07 | Bio-Rad Laboratories, Inc. | Anti-antibody reagent |
US20170234873A1 (en) * | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
US20170249445A1 (en) * | 2014-09-12 | 2017-08-31 | Blacktree Fitness Technologies Inc. | Portable devices and methods for measuring nutritional intake |
JP2017532285A (ja) * | 2014-01-28 | 2017-11-02 | バック インスティテュート フォー リサーチ オン エイジング | 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160000936A1 (en) * | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
-
2019
- 2019-02-21 US US16/970,796 patent/US20210109109A1/en active Pending
- 2019-02-21 CN CN201980014350.4A patent/CN112136048A/zh active Pending
- 2019-02-21 JP JP2020567440A patent/JP2021514479A/ja active Pending
- 2019-02-21 WO PCT/US2019/019047 patent/WO2019165145A1/en unknown
- 2019-02-21 EP EP19758041.8A patent/EP3762506A4/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011067214A (ja) * | 2001-11-09 | 2011-04-07 | Source Precision Medicine Inc | 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定 |
US20120122717A1 (en) * | 2006-10-06 | 2012-05-17 | Nestec S.A. | Composition and multiplex assays for measuring biological mediators of physiological health |
US20150126408A1 (en) * | 2007-08-20 | 2015-05-07 | Bio-Rad Laboratories, Inc. | Anti-antibody reagent |
US20100124756A1 (en) * | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
WO2011094535A2 (en) * | 2010-01-28 | 2011-08-04 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
US20120021414A1 (en) * | 2010-06-25 | 2012-01-26 | Howard Hughes Medical Institute | Diagnostic markers of immunosenescence and methods of use thereof |
JP2017532285A (ja) * | 2014-01-28 | 2017-11-02 | バック インスティテュート フォー リサーチ オン エイジング | 老化細胞を殺し、老化関連疾患および障害を処置するための方法と組成物 |
US20170249445A1 (en) * | 2014-09-12 | 2017-08-31 | Blacktree Fitness Technologies Inc. | Portable devices and methods for measuring nutritional intake |
US20170234873A1 (en) * | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
Non-Patent Citations (28)
Title |
---|
ALLEN MARK S.: "Five factor personality traits and inflammatory biomarkers in the English longitudinal study of agin", PERSONALITY AND INDIVIDUAL DIFFERENCES, vol. 111, JPN6023030704, 16 February 2017 (2017-02-16), pages 205 - 210, ISSN: 0005113708 * |
BIO-PLEX MULTIPLEX SYSTEM, JPN6022055347, 2016, ISSN: 0005113693 * |
BJORN GERDLE: "Signs of ongoing inflammation in female patients with chronic widespread pain", MEDICINE, vol. 96, no. 3, JPN6022055351, March 2017 (2017-03-01), pages 6130, ISSN: 0004955796 * |
CLAUDIO FRANCESCHI: "Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases", J GERONTOL A BIOL SCI MED SCI, vol. 69, no. 1, JPN6022055345, June 2014 (2014-06-01), pages 4 - 9, ISSN: 0005113695 * |
DAVID FURMAN: "Expression of specific inflammasome gene modules stratifies older individuals into two extreme clini", NATURE MEDICINE, vol. 23, no. 2, JPN6022055343, February 2017 (2017-02-01), pages 174 - 184, ISSN: 0005113697 * |
ELIZABETH A. MILES: "Age-related increases in circulating inflammatory markers in men are independent of BMI, blood press", ATHEROSCLEROSIS, vol. 196, JPN6022055348, 2008, pages 298 - 305, ISSN: 0005113692 * |
GALE CATHARINE R.: "Inflammatory markers and incident frailty in men and women: the English Longitudinal Study of Ageing", AGE, vol. 35, no. 6, JPN6023030702, December 2013 (2013-12-01), pages 2493 - 2501, ISSN: 0005113710 * |
GALINA V. SHURIN: "Dynamic alteration of soluble serum biomarkers in healthy aging", CYTOKINE, vol. 39, JPN6022055344, 2007, pages 123 - 129, XP022289353, ISSN: 0005113696, DOI: 10.1016/j.cyto.2007.06.006 * |
INGRID ELISIA: "Effect of age on chronic inflammation and responsiveness to bacterial and viral challenges", PLOS ONE, vol. 12, no. 11, JPN6023030695, 29 November 2017 (2017-11-29), pages 0188881, ISSN: 0005113715 * |
KAREN BANDEEN-ROCHE: "Measuring Systemic Inflammatory Regulation in Older Adults: Evidence and Utility", REJUVENATION RESEARCH, vol. 12, no. 6, JPN6022055342, 2009, pages 403 - 410, XP055631812, ISSN: 0005113698, DOI: 10.1089/rej.2009.0883 * |
KHAIBULLIN TIMUR: "Elevated Levels of Proinflammatory Cytokines in Cerebrospinal Fluid of Multiple Sclerosis Patients", FRONTIERS IN IMMUNOLOGY, vol. 8, JPN6023030703, 18 May 2017 (2017-05-18), pages 531, ISSN: 0005113709 * |
LI FANG-HUI: "Beneficial alterations in body composition, physical performance, oxidative stress, inflammatory mar", EXPERIMENTAL GERONTOLOGY, vol. 113, JPN6023030708, 9 October 2018 (2018-10-09), pages 150 - 162, ISSN: 0005113705 * |
MARCO PIO LA MANNA: "Identification of plasma biomarkers for discrimination between tuberculosis infection/disease and pu", PLOS ONE, vol. 13, no. 3, JPN6022055337, 18 March 2018 (2018-03-18), pages 0192664, XP055878604, ISSN: 0004955812, DOI: 10.1371/journal.pone.0192664 * |
MILLIPLEX MAP マルチプレックスアッセイキット, JPN6022055346, 2013, ISSN: 0005113694 * |
PHILIP C. CALDER: "Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the rol", AGEING RESEARCH REVIEWS, vol. 40, JPN6022055341, 9 September 2017 (2017-09-09), pages 95 - 119, ISSN: 0005113699 * |
PIER PAOLO SAINAGHI: "The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain-Barr", CYTOKINE, vol. 51, JPN6022055349, 2010, pages 138 - 143, XP027110325, ISSN: 0005113691 * |
PRADEEP TYAGI: "Association of inflammaging (inflammation + aging) with higher prevalence of OAB in elderly populati", INT UROL NEPHROL, vol. 46, no. 5, JPN6023030696, 10 December 2013 (2013-12-10), pages 871 - 877, ISSN: 0005113714 * |
RIMONDI ERIKA: "Involvement of TRAIL/TRAIL-receptors in human intestinal cell differentiation", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 206, no. 3, JPN6023030697, March 2006 (2006-03-01), pages 647 - 654, ISSN: 0005113713 * |
SANDI L. NAVARRO: "Reliability of Serum Biomarkers of Inflammation from Repeated Measures in Healthy Individuals", CANCER EPIDEMIOL BIOMARKERS PREV, vol. 21, no. 7, JPN6022055336, July 2012 (2012-07-01), pages 1167 - 1170, ISSN: 0004955811 * |
SARDELI AMANDA VEIGA: "Effect of resistance training on inflammatory markers of older adults: A meta-analysis", EXPERIMENTAL GERONTOLOGY, vol. 111, JPN6023030700, 30 July 2018 (2018-07-30), pages 188 - 196, XP085458544, ISSN: 0005113712, DOI: 10.1016/j.exger.2018.07.021 * |
SEAN X. LENG: "ELISA and Multiplex Technologies for Cytokine Measurement in Inflammation and Aging Research", JOURNAL OF GERONTOLOGY: MEDICAL SCIENCES, vol. 63, no. 8, JPN6022055339, 2008, pages 879 - 884, XP008154409, ISSN: 0005113701, DOI: 10.1093/gerona/63.8.879 * |
SHIJIN XIA: "An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2016, JPN6022055340, 2016, pages 8426874, ISSN: 0005113700 * |
SHUYANG WANG: "Feature Selection Guided Auto-Encoder", PROCEEDINGS OF THE THIRTY-FIRST AAAI CONFERENCE ON ARTIFICIAL INTELLIGENCE (AAAI-17), vol. 3, no. 1, JPN6022055350, 13 February 2017 (2017-02-13), pages 2725 - 2731, ISSN: 0005113690 * |
TAMAS FULOP: "immunosenescence and inflamm-Aging As Two Sides of the Same Coin: Friends or Foes?", FRONTIERS IN IMMUNOLOGY, vol. 8, JPN6022055338, 10 January 2018 (2018-01-10), pages 1960, ISSN: 0005113702 * |
TUSHAR SINGH: "Inflammatory markers in population studies of aging", AGEING RESEARCH REVIEWS, vol. 10, JPN6022055335, 8 December 2010 (2010-12-08), pages 319 - 329, ISSN: 0005113703 * |
小川純人: "老化の分子生物学 4 老化と炎症", BIO CLINICA, vol. 29, no. 1, JPN6023030707, 10 January 2014 (2014-01-10), pages 29 - 32, ISSN: 0005113706 * |
波岡那由太: "アルツハイマー病患者のフレイルに関連した酸化ストレスと炎症", 東京医科大学雑誌, vol. 74, no. 3, JPN6023030701, 30 July 2016 (2016-07-30), pages 344 - 345, ISSN: 0005113711 * |
波岡那由太: "アルツハイマー病患者の身体的フレイルに関連した酸化ストレスと炎症マーカー", 日本神経学会学術大会プログラム・抄録集, vol. 57, JPN6023030706, 2016, pages 560, ISSN: 0005113707 * |
Also Published As
Publication number | Publication date |
---|---|
EP3762506A4 (en) | 2022-03-23 |
EP3762506A1 (en) | 2021-01-13 |
US20210109109A1 (en) | 2021-04-15 |
WO2019165145A1 (en) | 2019-08-29 |
CN112136048A (zh) | 2020-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021514479A (ja) | 全身性慢性炎症加齢を測定する方法 | |
Sayed et al. | An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging | |
Zhang et al. | Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis | |
Shen-Orr et al. | Defective signaling in the JAK-STAT pathway tracks with chronic inflammation and cardiovascular risk in aging humans | |
Healy et al. | Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events | |
Baggish et al. | Rapid upregulation and clearance of distinct circulating microRNAs after prolonged aerobic exercise | |
JP4520157B2 (ja) | 敗血症の早期検出 | |
US11104953B2 (en) | Septic shock endotyping strategy and mortality risk for clinical application | |
ES2324751B1 (es) | Metodos y kits para diagnosticar y/o pronosticar el estado de tolerancia en el trasplante de higado. | |
Sayed et al. | An inflammatory clock predicts multi-morbidity, immunosenescence and cardiovascular aging in humans | |
Geng et al. | Altered monocyte subsets in Kawasaki disease revealed by single-cell RNA-sequencing | |
US11482301B2 (en) | Gene expression analysis techniques using gene rankings and statistical models for identifying biological sample characteristics | |
Park et al. | Transcriptomic analysis of human IL‐7 receptor alpha low and high effector memory CD8+ T cells reveals an age‐associated signature linked to influenza vaccine response in older adults | |
Wang et al. | Toll‐like receptor‐4 and mitogen‐activated protein kinase signal system are involved in activation of dendritic cells in patients with acute coronary syndrome | |
Zagorski et al. | Transcriptional profile of right ventricular tissue during acute pulmonary embolism in rats | |
VanBuren et al. | Blood gene expression signatures associate with heart failure outcomes | |
CN114107509A (zh) | 一种肝癌预后标记物及其应用 | |
Heimlich et al. | Mutated cells mediate distinct inflammatory responses in clonal hematopoiesis | |
US7998682B2 (en) | Method for assessing atherosclerosis by measuring expression of FOS or DUSP1 in monocytes | |
Bian et al. | Systemic blood predictors of elevated pulmonary artery pressure assessed by non-invasive echocardiography after acute exposure to high altitude: A prospective cohort study | |
Furman et al. | An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging | |
Sitlinger et al. | Higher Physical Fitness Regulates In Vitro Tumor Cell Growth in Older Adults with Treatment Naïve Chronic Lymphocytic Leukemia (CLL) | |
Bawamia | Telomerase Activation to reverse Immunosenescence in elderly patients with Acute Coronary Syndrome | |
Read | Development and application of combinatorial single cell methods to tissue physiology and disease | |
Kort et al. | The inflammasome of circulatory collapse: single cell analysis of survival on extracorporeal life support |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20220119 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220119 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220301 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230725 |